triazoles has been researched along with pyrrolopyrimidine in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Cho, WJ; Choi, S; Chung, YK; Han, SY; Kang, KW; Kim, J; Kim, YC; Ko, H; Lee, HJ; Lee, SM; Mukai, C; Yoon, KB | 1 |
| Duan, Y; Li, X; Liu, X; Tang, Q; Wang, C; Wang, L; Xiao, Z; Zhao, B; Zheng, P; Zhu, W | 1 |
| Jeong, PH; Jung, JH; Kim, W; Kim, YC; Lee, SM | 1 |
3 other study(ies) available for triazoles and pyrrolopyrimidine
| Article | Year |
|---|---|
The discovery of 2,5-isomers of triazole-pyrrolopyrimidine as selective Janus kinase 2 (JAK2) inhibitors versus JAK1 and JAK3.
Topics: Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Discovery; Humans; Janus Kinase 1; Janus Kinase 2; Janus Kinase 3; Molecular Structure; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Stereoisomerism; Structure-Activity Relationship; Triazoles | 2016 |
Discovery of novel pyrrolopyrimidine/pyrazolopyrimidine derivatives bearing 1,2,3-triazole moiety as c-Met kinase inhibitors.
Topics: Antineoplastic Agents; Binding Sites; Cell Line, Tumor; Cell Survival; Drug Design; Drug Screening Assays, Antitumor; G2 Phase Cell Cycle Checkpoints; Hep G2 Cells; Humans; M Phase Cell Cycle Checkpoints; MCF-7 Cells; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-met; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; Structure-Activity Relationship; Triazoles | 2018 |
Synthesis and structure-activity relationship studies of 1,5-isomers of triazole-pyrrolopyrimidine as selective Janus kinase 1 (JAK1) inhibitors.
Topics: Crystallography, X-Ray; Dose-Response Relationship, Drug; Humans; Janus Kinase 1; Janus Kinase Inhibitors; Models, Molecular; Molecular Structure; Pyrimidines; Pyrroles; Structure-Activity Relationship; Triazoles | 2022 |